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Abstract Background and objectives: Arterial (A) and
venous (V) plasma nicotine and cotinine concentrations
were measured after nasal nicotine spray in tobacco
smokers of both genders. The hypothesis for this re-
search was that a greater A/V dierence in plasma nic-
otine would be present in males than females because
males have greater skeletal muscle mass to bind nicotine.
Subjects and methods: Nine male and nine female healthy
adult smokers were studied. They all abstained from use
of tobacco overnight for 10 h or more prior to the study.
Nicotine nasal spray was given in doses of 1±2.5 mg to-
tal, with half in each nostril while the subject was supine.
Both A and V blood samples were obtained prior to and
3, 6, 10, 15, 20, and 30 min post-nasal nicotine spray.
Results and conclusions: Nasal nicotine administration
produced greater A than V plasma levels. There were no
gender dierences in A/V nicotine concentrations, dis-
proving the above hypothesis, suggesting that other
physiochemical factors besides skeletal muscle mass must
be involved. Heart rate increases correlated well with
arterial plasma nicotine levels (r  0.77). Males had less
variance than females in the expected increase in arterial
plasma nicotine concentrations with increased number of
nasal sprays. Although there was considerable overlap,
mean A cotinine concentrations were consistently
slightly larger than V concentrations.
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Introduction
It is generally agreed that venous blood drug concen-
trations are a valid index of arterial concentrations but
only when equilibrium throughout the organism is
achieved. Arterial blood perfuses all body tissues before
equilibrium and a signi®cant portion of drug may be
taken up by these tissues. Consequently, the concentra-
tion of drug in arterial blood is a better index of the
amount delivered to the site of pharmacological action.
During this period, arterial concentrations would be
more likely to correlate with pharmacological responses.
However, arterial access, even in a peripheral extremity,
is a more invasive procedure than venous access. This
practical consideration prompts most investigators to
obtain only venous blood samples. As part of a quan-
titative study using nasal nicotine administration on
regional cerebral blood ¯ow, it was possible to obtain
both arterial and venous blood samples for assay of
nicotine and cotinine from the forearms of a group of
adult male and female tobacco smokers who abstained
from tobacco use overnight prior to the study.
When samples are obtained from vessels in the arm,
the dierence between arterial and venous concentra-
tions prior to equilibrium re¯ects primarily the distri-
bution of nicotine into tissues in the forearm. The
change of venous nicotine concentration over time is
aected by the arterial concentration, the tissue to blood
partition ratio, the volume of tissue, and the rate of
tissue perfusion. Several investigators have reported
nicotine arterial/venous (A/V) concentrations following
smoking, nasal and/or intravenous nicotine in adult
male volunteers [1±4]. It is well known that, in general,
adult males have a larger skeletal muscle mass than
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females [5]. Hence, the hypothesis of the present research
was that males would have a greater nicotine A/V
dierence than females due to greater distribution of
nicotine in skeletal muscle. This manuscript describes
data that do not support this super®cially attractive
hypothesis, indicating that many factors aect the ®nal
concentration of a drug leaving a tissue. In addition to
the mass of tissue, this concentration is certainly aected
by the partition of nicotine between blood and skeletal
muscle. In the process of completing this study, several
other interesting relationships were discovered.
Subjects and methods
This study was approved by the Investigational Review Board for
Human Subject Research at The University of Michigan Medical
Center. All candidates who agreed to participate provided in-
formed consent. Subjects were recruited through advertisements in
local newspapers and via community bulletin boards. Candidates
who appeared to be eligible on the basis of a preliminary telephone
screen were invited to a screening interview, at which time the study
was explained. A physical examination was performed and labo-
ratory tests were obtained, including a complete blood count,
electrolytes, liver function tests, a urinalysis, and a urine toxicology
screen for abused drugs. Additionally, all candidates underwent a
psychiatric screening interview using the Diagnostic Interview
Schedule. Women were given a pregnancy test prior to inclusion in
the study. Subjects who met the above criteria completed a Fag-
erstroÈ m test [6] to provide a preliminary assessment of degree of
nicotine dependence.
Inclusion and exclusion criteria
Subjects were male or female tobacco smokers (>15±40 cigarettes
per day), between 18 years and 52 years of age, in good physical
health, and not taking any medications (except oral contraceptives
or replacement hormones). Individuals suering from renal, he-
patic, cardiovascular, hematological, neurological, psychiatric, or
endocrinological disease were excluded. Fertile women who were
not using an acceptable method of birth control (oral contracep-
tives, a barrier method, intrauterine device, or levonorgestrel
implants) were excluded. Also, those who met criteria for psycho-
active substance abuse disorder on the Diagnostic Interview
Schedule were excluded, as were those who revealed evidence of
recent use of an abused substance in the urine toxicological screen.
Procedure
Subjects included in the study were taught to use a Food and Drug
Administration (FDA) approved nicotine nasal spray device prior
to the study day. This study was conducted in conjunction with an
evaluation of regional cerebral blood ¯ow. Subjects reported to the
PET suite of the Nuclear Medicine Division of University Hospital
at 0800 hours on the day of the study, following overnight absti-
nence from tobacco and nicotine spray (>10 h). A sample of ex-
pired air was analyzed for carbon monoxide (CO) in parts per
million (ppm). Expired air CO levels higher than 10 ppm in the
subject required an extensive interview to ascertain possible non-
compliance with the no-smoking directive within the past 10 h.
Also electrocardiogram (ECG) and blood pressure were monitored
throughout the study (Marquette Electronics, Inc., Milwaukee,
Wisc.; Series 7000 monitor).
Following an explanation of the imaging procedure, the subject
lay supine on the positron emission tomography (PET) frame, and
a series of six PET scans was conducted using H2
15O to determine
regional cerebral blood ¯ow (rCBF). The methodology and results
of the rCBF studies will be reported elsewhere [7]. Both venous and
arterial access lines were placed in the forearms of the subjects prior
to the rCBF sessions. Just before the ®fth scan, nicotine spray
(0.5 mg/spray) was administered intranasally. Two to ®ve sprays
were given, depending on the volunteer's ability to tolerate the
nicotine. Arterial and venous blood samples for nicotine and
cotinine were withdrawn before and after the ®fth and sixth scans.
Samples were drawn prior to and at 3, 6, 10, 15, 20 and 30 min
following the nicotine dose. Samples were collected in standard
5-ml vacutainer tubes containing ethylene diamine tetraacetic acid
(EDTA) and stored immediately on crushed ice. Immediately fol-
lowing completion of the study, the samples were centrifuged and
plasma aliquots were frozen at )20 °C until analysis. Venous and
arterial samples were analyzed using high-performance liquid
chromatography (HPLC) techniques [8]. The interassay coecients
of variation for nicotine and cotinine were 10.8% and 5.5%, re-
spectively. The intraassay coecients of variation were 9.0% and
5.8% for nicotine and cotinine, respectively. The sensitivity of the
assay was 1 ng/ml for nicotine and 3 ng/ml for cotinine.
Data analysis
The maximum concentration (Cmax), the time of maximum con-
centration (tmax), and the area under the plasma concentration
versus time curve (AUC) from 0 min to 30 min were determined for
both arterial and venous nicotine concentrations directly from the
observed data and by the linear trapezoidal rule. Analyses were run
using raw data values as well as data adjusted for baseline nicotine
concentration. The arterial and venous pharmacokinetic parameters
were compared using paired t-tests. The pharmacokinetic values for
males and females were compared using unpaired t-tests. Venous
and arterial nicotine concentrations were compared using analysis of
variance (ANOVA) for repeated measures. All statistical tests were
conducted using SAS software [9] on a Macintosh power personal
computer. Change in heart rate and arterial nicotine concentrations
were ®tted to the sigmoid Emax model using PC NONLIN [10].
Results
Nineteen smokers were recruited (ten men, nine women).
Data from one male subject were discarded, because the
number of blood samples obtained was inadequate to
determine pharmacokinetic parameters. Results are re-
ported for 18 subjects (nine men and nine women). The
mean age of the women was 33.7  8.38 years (range
20±46 years) and the mean age of the men was 30.4 
10.6 years (range 20±52 years). Outcomes of the ana-
lyses did not dier when adjusted for baseline plasma
nicotine concentrations.
Overall, when arterial were compared with venous
nicotine concentrations, ANOVA for repeated measures
revealed both group (P < 0.01) and time (P < 0.01) ef-
fects, indicating that arterial concentrations were consis-
tently and signi®cantly higher than venous concentrations
and that concentrations varied signi®cantly over time
(Fig. 1). The AUC and the Cmax values were also signi®-
cantly larger when arterial were compared with venous
concentrations (P < 0.001, for both). Also, tmax occurred
earlier in arterial than in venous samples (5.06 min vs
16.66 min, respectively; Table 1). A comparison of the
results by gender revealed no signi®cant eects for Cmax,
AUC, tmax, or the ratio of arterial to venousCmax orAUC.
Mean arterial cotinine concentrations were consis-
tently slightly greater than mean venous levels, especially
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20 min and 30 min post-nicotine nasal spray (Fig. 1).
The standard errors overlapped considerably, but a trend
analysis indicated that the mean dierences were signi-
®cant (P < 0.05). The arterial, but not the venous, Cmax
was signi®cantly correlated with the maximum change of
heart rate (P < 0.001, r  0.77; Fig. 2). A more mean-
ingful relationship between change in heart rate and
arterial blood concentration might be obtained by ®tting
the data to a sigmoid Emax model. Of the 18 subjects, an
acceptable ®t to the sigmoid Emax model was achieved in
10 (Table 2). The mean maximum change in heart rate
was 45.5 bpm and the EC50 was 16.8 ng/ml (Fig. 3).
Two to ®ve nasal sprays of nicotine were administered
to each of the volunteers. The females showed much
more variability in the boost in arterial nicotine than the
males (Table 1). No signi®cant linear relationship could
be obtained between the number of nasal sprays and the
increase in arterial nicotine levels when the female and
male data were combined or for the females alone. The
males had a correlation coecient of r  0.74 (P <
0.05), indicating a linear increase in arterial nicotine as a
function of number of nasal nicotine sprays.
Discussion
Possible gender-based dierences in nicotine plasma
concentrations following intranasal nicotine have not
been explored previously. The concentration of nicotine
in blood is aected by both the route of administration
Fig. 1 Mean arterial and ve-
nous plasma nicotine and coti-
nine concentrations following
nasal nicotine administration.
The mean  SEM of 18 to-
bacco smokers who were absti-
nent overnight is plotted before
and after nasal nicotine spray to
both nostrils
Table 1 Gender, body weight, maximum concentration (Cmax), time to Cmax (tmax), and the area under the curve (AUC) for arterial and






sprays Cmax (ng/ml) tmax (min) AUC Cmax (ng/ml) tmax (min) AUC
Female
1 54.6 4 25.1 10 532.9 12.9 16 294.3
4 61.8 2 8.1 6 164.4 4.5 19 99.9
5 47.7 4 30.8 2 485.2 10.6 21 282.3
6 59.1 3 16.3 3 270.2 8.9 60 222.6
9 61.4 NA 12.0 2 255.5 4.9 9 141.9
10 57.3 4 11.5 7 117.8 6.4 15 75.8
12 59.1 3 22.0 2 269.7 5.5 30 130.9
16 68.2 4 15.4 7 244.5 3.8 20 115.5
19 97.7 2 18.7 3 305.4 6.8 9 167.0
Mean  SD 63.0  14.2 3.3  0.9 17.8  7.2 4.7  2.9 294.8  135.1 7.2  2.9 23.3  15.8 170.0  79.0
Male
2 77.3 2 15.3 7 336.9 9.6 7 226.8
3 88.6 2 16.2 7 285.9 7.9 10 186.5
8 81.8 4 11.1 3 170.0 3.9 20 106.9
11 84.1 3 11.7 6 123.6 6.2 14 100.4
13 65.9 4 24.2 2 551.7 19.6 9 442.4
14 72.7 2.5 13.5 3 250.1 11.7 4 193.9
15 86.4 5 19.0 8 275.5 9.3 15 212.8
17 75.0 4 13.2 6 244.5 3.8 20 95.6
18 75.0 4 21.3 7 428.3 9.7 7 266.3
Mean  SD 78.0  7.7 3.4  1.1 16.2  4.5 5.4  2.2 296.3  130.1 9.1  4.8 11.8  5.8 203.5  108.2
Overall
mean  SD
70.5  13.5 3.3  1.0 17.0  5.9 5.1  2.5 295.5  128.7 8.2  4.0 17.6  13.0 186.8  93.5
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and the site of blood sampling. When nicotine is admin-
istered intranasally, it is absorbed through the numerous
small vessels surrounding the nasal sinuses. The veins of
the nasal cavity form a cavernous plexus beneath the
mucous membrane. In addition, arteriovenous commu-
nications are present [11]. These vessels ultimately drain
into the superior vena cava. Venous nicotine is carried to
the right side of the heart, followed by the lungs, where
some nicotine is undoubtedly extracted by lung tissue.
Following transport through the lungs, the oxygenated
arterial blood is transported through the left side of the
heart, carrying nicotine to all body organs and tissues.
Substances that are used primarily for their central
nervous system eects, such as nicotine, are usually
highly lipophilic and enter the brain shortly following
ingestion. In the immediate period following a single
dose of drug, the venous concentrations generally do not
closely re¯ect body tissue concentrations in organs due
to distributional lag time and distribution into or bio-
transformation of the drug by body tissues. It is known
that there is a pronounced dierence between the arterial
and venous concentrations of nicotine following intra-
venous injection, smoking, or intranasal administration
of nicotine [1±4]. This dierential between venous and
arterial nicotine concentrations is due to the relationship
between the site of administration of nicotine in relation
to the site of measurement [12]. Because of nicotine
distribution into and binding to various body tissues
following intravenous or intrapulmonary administra-
tion, arterial concentrations are higher than venous
concentrations in the short period following acute nic-
otine administration, until the drug has accumulated in
the tissues and the net removal from arterial blood be-
comes zero [12, 13].
The hypothesis that men will exhibit a greater A/V
dierence in nicotine concentrations due to greater
skeletal muscle mass than women was not supported by
the results of the present study. It is possible that, in the
forearm, the larger skeletal muscle mass in men is oset
by a higher proportion of subcutaneous fat in women.
The blood perfusion rate is slightly higher in fat
(0.03 ml/min/ml tissue) than in inactive skeletal muscle
(0.025 ml/min/ml tissue) [14]. In addition to perfusion
rate and volume of tissue, the time to reach equilibrium
depends on the tissue partition coecient. Nicotine has
a very high octanol±water coecient (15:1 at pH 7),
which would contribute to rapid uptake in fatty tissues
that is perfusion rate limited. For a tissue where there is
no elimination, the mass/balance of a compound enter-
ing and leaving a tissue is given by:
V dc=dt  QCin ÿ Cin=Kp
where V is the physical volume of the tissue, c is the drug
concentration in the tissue, t is the time, Q is the blood
¯ow to the tissue, Cin is the drug concentration entering
the tissue, and Kp is the partition of the drug between
blood and the tissue. Thus, there are many factors that
aect the ®nal concentration of a drug leaving a tissue.
In the case of nicotine, the dominant factor is probably
partition and not the physical volume of skeletal
muscle of men versus women. It is known that the
Fig. 2 Relationship between change of heart rate and the maximal
arterial plasma nicotine concentration. The correlation between the
arterial concentrations and heart rate per minute was r  0.77 in all 18
patients
Table 2 Best ®t Emax, ED50, and gamma values for ten subjects
(mean  SEM)
Subject no. Emax EC50 Gamma
1 52.1  74.3 15.7  45.5 14.2  2334.9
3 71.2  1044.4 31.4  272.1 2.3  4.0
6 27.4  2.4 6.9  0.25 9.2  3.9
9 15.9  8.0 4.1  3.0 2.0  2.9
12 44.1  14.9 6.4  1.9 1.8  2.2
13 34.1  105.4 33.0  111.4 1.6  1.8
14 56.3  813.5 21.8  518.9 1.1  5.8
15 36.7  73.1 10.1  13.8 3.1  5.0
16 44.2  89.1 13.3  32.8 1.6  2.0
17 73.3  815.7 25.4  369.3 1.3  3.8
Fig. 3 Relationship between change of heart rate and arterial plasma
nicotine concentrations. Mean Emax, EC50, and gamma are depicted as
the solid line. The arterial plasma concentrations and changes in heart
rate from ten subjects are reported
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pharmacokinetics of nicotine, when measured in venous
blood, do not dier between men and women [15].
The trend for mean cotinine in arterial plasma to be
greater than mean venous concentrations was unex-
pected. Various tissues, especially the liver and lung,
biotransform nicotine to cotinine. Arterial blood going
to and venous blood returning from the hand and
forearm would not be expected to show any dierences
in concentration with a more water-soluble substance,
such as cotinine, relative to nicotine. Apparently, the
tissues in the forearm and hand retain a small amount of
cotinine, especially 20 min and 30 min post nasal nico-
tine. After overnight nicotine deprivation of 10 h or
more, the mean cotinine levels in both artery and vein
were almost identical, indicating equilibration did occur
and was almost complete.
Following nasal insuation of nicotine, it has been
estimated that approximately 20±30% of a nicotine dose
is transported by the oral cavity and esophagus to the
stomach. In the present study, the subjects were supine.
It is quite likely that some intranasally administered
nicotine also dripped into the pharynx where it was
swallowed and ultimately absorbed, slowly, via the
gastrointestinal tract. In addition, following nicotine
nasal spray, the maximum arterial nicotine concentra-
tions were higher, and occurred earlier, than the venous
nicotine concentrations. Similar results have been re-
ported previously [1]. The mean peak arterial concen-
tration occurred after approximately 5 min in the
present study. The actual value of the peak concentra-
tion diered from that found in the previous study of
Gourlay and Benowitz [1], but this is not surprising
because diering doses of nasal spray were delivered in
our study.
In a study of smoking suppression following a 15-
lg/kg and 30-lg/kg dose of nasal nicotine spray, sub-
sequent cigarette smoking was suppressed to a greater
extent in men than in women [16]. This is consistent with
the present ®nding that women have greater variability
in absorbing nasal nicotine than men. However, mean
venous nicotine concentrations did not dier between
men and women. Neither the pharmacokinetic parame-
ters nor the relationship between change in heart rate
and nicotine concentration showed any gender depen-
dence. There was a statistically signi®cant correlation
between the change from baseline to maximum heart
rate and maximum arterial nicotine concentration.
Nevertheless, the correlation between these two mea-
sures was not aected by gender. In the present study,
there was no gender dierence in heart rate response. It
is possible that heart rate response is not a good measure
of central nicotine response and does not correlate well
with other central nervous system responses to nicotine,
such as suppression of craving or anxiety reduction.
Unfortunately, at this time, there are no good objective
measures that have been shown to unambiguously re¯ect
central nervous system dynamic response to nicotine.
It is also possible that the small sample size may have
caused a type-II error and obscured any gender-related
dierences that may, in fact, exist. This is unlikely be-
cause there was not even a trend indicating possible
gender dependence of nicotine pharmacokinetics. The
only gender dierence noted in the present study was
that the relationship between dose and arterial plasma
concentration was more consistent in men than in
women. A larger number of subjects is needed to show
variation in arterial nicotine with the same number of
nasal sprays in both genders.
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